Surface Imaging-Guided Adaptive Radiotherapy (ART): Imaging Protocol and Verification for Inter- and Intra-Fractional Motion Managements

Abstract

<h3>Purpose/Objective(s)</h3> CBCT-guided adaptive radiotherapy (CT-ART) has proven to account for inter-fractional anatomic changes. However, no commercial solution for intra-fractional respiratory motion management existed in CT-ART. Therefore, we investigated intra-fractional motion-managed treatment strategies in CT-ART (or Image-guided RT: IGRT) using optical surface imaging combined with <i>in-situ</i> CBCTs. <h3>Materials/Methods</h3> Eight of ten cancer patients with mobile lower lung or upper abdominal malignancies have completed CT-ART (or IGRT) using Ethos radiotherapy in an IRB-approved clinical trial (phase I). Four of the eight patients underwent additional MR simulations, including cine MRIs, to estimate the tumor/abdominal skin motion correlation. In CT-ART, a pre-configured gating window (±2 mm in vertical position) on surface imaging was used for manually triggering intra-fractional CBCT and treatment beam irradiation in breath-hold (six patients for exhalation and two patients for inhalation). A donut-shaped imaging-surrogate on patient's abdomen was used to localize Region of Interest (ROI) of the abdomen on CBCTs. Two inter-fractional CBCTs at exhalation and inhalation in each fraction were acquired to verify the tumor/imaging-surrogate motions range. Intra-fractional CBCTs were used to quantify the residual motion of the tumor/imaging-surrogate within the pre-configured gating window. Tumor motion was measured by tracking the position of a tumor centroid. <h3>Results</h3> The pre-configured gating window on surface imaging was confirmed based on the correlation of the tumor and abdominal skin motions using cine MRIs. Thirty-six pairs of inter-fractional CBCTs and 100 intra-fractional CBCTs from 36 fractions were analyzed (13 fractions for IGRT and 23 for ART). In the motion range study from the inter-fractional CBCTs, the values of mean ± std were 17.3 ± 12.0 mm in the SI direction for the tumors and 16.6 ± 7.9 mm in the AP direction for the imaging-surrogate, respectively. The residual motion of the imaging-surrogate from intra-fractional CBCTs was 2.5 ± 2.1 mm for SI, 2.3 ± 2.0 mm for RL, and 2.1 ± 2.3 mm for AP directions. The residual motion of the tumors was 2.4 ± 3.1 mm for SI, 2.3 ± 2.3 mm for RL, and 2.2 ± 2.0 mm for AP directions. Trends in the residual motion during the course of treatment fractions and over time through delivery were stable. Inter-fractional residual motions of the tumors were 2.3 ± 0.8 mm for SI, 2.3 ± 0.6 mm for RL, and 2.2 ± 0.7 mm for AP directions. Intra-fractional residual motions of the tumors were 2.4 ± 0.9 mm for SI, 2.4 ± 0.7 mm for RL, and 3.2 ± 1.3 mm for AP. <h3>Conclusion</h3> We demonstrated the inter- and intra-fractional motion-managed treatment strategies in CBCT-guided ART using surface imaging. Since the residual motion of the tumors was comparable to that of the imaging-surrogate within clinical PTV margins (5 mm) but a bit larger than the pre-configured gating window, additional caution is needed with intra-fractional motion management in CT-ART using the optical surface imaging.